Fortress Biotech, Inc. (FBIO)

2.77 -1.07% (-0.03)

Over 5Y: -94.3%

2026-08-28
20 40
2021 2022 2023 2024 2025 2026

Financials Quarterly

Q3 '25 — Revenue: 17.6M Q3 '25 — Operating Cash Flow: -6.1M Q3 '25 — Net Income: 5.8M Q4 '25 — Revenue: 16.1M Q4 '25 — Operating Cash Flow: -12.5M Q4 '25 — Net Income: -3.9M Q1 '26 — Revenue: 16M Q1 '26 — Operating Cash Flow: 203.9M Q1 '26 — Net Income: 110.4M Q2 '26 — Revenue: 18.7M Q2 '26 — Operating Cash Flow: -59.3M Q2 '26 — Net Income: -468K 0 60M 120M 180M 240M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-12-31, -123 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

2.8
OE margin 168.9%
SBC / sales 15.0%
Oper. margin -42.9%
ROIC -904.2%
Accruals -4.5%
FCF margin 183.9%
OCF margin 183.9%
Profit margin 163.3%
ROA 35.3%
ROE 68.1%
Gross margin 65.6%
EBITDA margin -42.3%
ROCE -11.5%
Capex / sales —
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.5
ND/EBITDA —
Cash / Debt 5.6×
Debt payback 0.0 yr
Payout 0.45%
Quick ratio 3.8×
Debt / Eq 0.21×
F-score 5.0 pts
Cash runway —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.7
Sales/sh Y/Y -14.0%
Sales Q/Q +14.0%
Div. growth -4.3%
Shares change +34.3%
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.